Does anticoagulation in Eisenmenger syndrome impact long-term survival?

Congenital Heart Disease
Julio SandovalCraig S Broberg

Abstract

To determine the impact of anticoagulation on survival in Eisenmenger syndrome. The use of anticoagulation for primary prevention of adverse events in patients with Eisenmenger syndrome has been proposed but not studied. Strong arguments have been made both for and against anticoagulation based on the known risk of hemoptysis and pulmonary vascular thrombosis. Retrospective cohort study at a tertiary referral hospital. One hundred forty-four patients with established Eisenmenger physiology all underwent initial laboratory, echocardiographic, and catheterization evaluation after initial referral. We retrospectively identified patients who were started on anticoagulation (AC) and compared them to patients who did not receive anticoagulation therapy (non-AC). Baseline variables were compared between groups, as well as between survivors and nonsurvivors. Analyses of prognostic factors and survival were done using Cox and Kaplan-Meier methods. The primary outcome was death since time of baseline evaluation. We identified 48 anticoagulated and 44 non-anticoagulated patients with Eisenmenger physiology (oxygen saturation 82 ± 9%, PaO(2) 48 ± 8 mm Hg, hemoglobin 18.6 ± 4 g/dL). More atrial septal defect patients were in the AC group, b...Continue Reading

References

Sep 1, 1988·Annals of Internal Medicine·J K PerloffG B Wright
Mar 3, 1998·International Journal of Cardiology·J Somerville
Jan 14, 1999·European Heart Journal·L DalientoS Stone
May 13, 1999·Nederlands tijdschrift voor geneeskunde·J W Roos-HesselinkS E Spitaels
Jul 10, 1999·Journal of the American College of Cardiology·K NiwaP D Miner
Sep 25, 1999·The American Journal of Cardiology·W J CantorS C Siu
Dec 10, 2003·Journal of the American College of Cardiology·Candice K SilversidesJudith Therrien
Jun 15, 2004·Journal of the American College of Cardiology·Nazzareno GalièLewis J Rubin
May 19, 2005·Revista española de cardiología·Beatriz Bouzas, Michael A Gatzoulis
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Jul 18, 2006·Journal of the American College of Cardiology·Craig S BrobergMichael A Gatzoulis
Feb 28, 2007·Circulation·Gerhard-Paul Diller, Michael A Gatzoulis
Aug 19, 2007·Journal of the American College of Cardiology·Craig S BrobergMichael A Gatzoulis

❮ Previous
Next ❯

Citations

Oct 12, 2013·Paediatric Drugs·Erika E Vorhies, David Dunbar Ivy
Nov 4, 2015·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Tamara RoldanAaron B Waxman
Feb 11, 2015·Expert Opinion on Pharmacotherapy·Frédéric LadorMaurice Beghetti
Oct 23, 2013·Journal of cardiology·Taku InoharaUNKNOWN Research Committee of the Japanese Society of Adult Congenital Heart Disease
Feb 5, 2015·Archivos de cardiología de México·Juan Calderón-ColmeneroMiguel Beltrán Gámez
May 29, 2018·Journal of Thrombosis and Haemostasis : JTH·Barry KevaneFionnuala Ní Áinle
Nov 5, 2015·Circulation·Steven H AbmanUNKNOWN American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical C
Feb 26, 2019·Journal of the American Heart Association·Alexander C EgbeHeidi M Connolly
Oct 28, 2016·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Anna RemkováMonika Kaldarárová
Jan 22, 2020·Paediatric Drugs·Catherine M AvitabileDavid Dunbar Ivy
Jun 1, 2020·Current Pharmaceutical Design·Christina ChrysohoouDimitrios Tousoulis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.